XRTX - XORTX Corp Total Debt to Capital

XORTX Therapeutics Inc. (XRTX) focuses its biotech business on advancing its primary renal drug, limiting its scope to basic interactions with contract manufacturing organizations. The available price action vector based on the total debt-to-equity ratio is 0.00. XORTX Therapeutics Inc. (XRTX) is building a closed scientific environment for precision therapy of immune failures via proprietary xanthine oxidase inhibitors, while its resilience relies on the development of targeted agents in Canadian centers.

XORTX Therapeutics Inc. specializes in developing long-term therapies for chronic kidney diseases, which requires significant R&D capital expenditures. By analyzing the debt-to-equity ratio, an investor assesses the proportion of borrowed funds relative to equity, which helps determine bankruptcy risk amid rising interest rates and identify potential value traps in the fundamental valuation of the business.